Researchers at UVA Health have developed a novel microRNA therapy designed to cross the blood-brain barrier and target multiple cancer-promoting pathways in glioblastoma simultaneously, offering a potential path forward for a disease where median survival remains stuck at approximately 15 months.
Targeting Multiple Genetic Pathways in Glioblastoma
Glioblastoma remains exceptionally difficult to treat because tumor cells infiltrate surrounding healthy tissue, making complete surgical removal impossible. Furthermore, multiple genes are deregulated, and the specific combination of altered molecules varies widely between patients and even among different cells inside a single tumor. While therapies designed to hit multiple deregulated molecules at once could prove effective, developing such drugs has historically led to exponentially increasing toxicity without advancing to clinical use.
To bypass these limitations, the research team created a multistep identification process to find microRNAs capable of regulating multiple genes at once. Using a mapping technique known as PAR-CLIP alongside computational algorithms and gene expression data from normal brain samples, the group evaluated 611 microRNAs. This analysis narrowed the candidates down to two tumor-suppressive options, miR-340 and miR-382, and one oncogenic target, miR-17.
Validating MicroRNAs in Cell and Animal Models
The investigators tested their selected microRNAs in established glioblastoma cell lines and patient-derived glioblastoma stem cell lines. Manipulating miR-340, miR-382, and miR-17 successfully suppressed cancer-promoting genes, reduced cell proliferation and invasion, and impaired self-renewal in patient-derived stem cells.
When the team implanted these modified glioblastoma cells into mice, all three microRNA manipulations significantly reduced tumor growth compared with control groups. Moving to treat established tumors in mice, the researchers faced the second major hurdle of glioblastoma treatment: the blood-brain barrier, which normally blocks drug delivery to the central nervous system.
Overcoming the Blood-Brain Barrier With Focused Ultrasound
To deliver the genetic material directly into established brain tumors, the team utilized microbubble-enhanced transcranial focused ultrasound (MB-FUS) to temporarily open the blood-brain barrier. They then administered brain-penetrating nanoparticles carrying genetic instructions for either miR-340 or miR-382. A recent human clinical study has demonstrated that pairing MB-FUS with standard therapy significantly increases survival rates.
Delivering miR-340 or miR-382 via this focused ultrasound method significantly reduced tumor burden and extended survival in mice compared with control groups. The researchers replicated these positive outcomes in mice bearing tumors grown from patient-derived glioblastoma stem cells. When the team administered the same nanoparticles without first using MB-FUS to open the blood-brain barrier, they observed no substantial reduction in tumor burden.
Frequently Asked Questions About the New Glioblastoma Therapy
How does focused ultrasound open the blood-brain barrier?
Researchers inject microscopic gas bubbles into the bloodstream and apply focused ultrasound waves to a specific region of the brain. The ultrasound causes the microbubbles to expand and contract rapidly, which gently and temporarily loosens the tight junctions of the blood-brain barrier to allow therapeutic nanoparticles to pass through.
What makes miR-340 and miR-382 effective against glioblastoma?
Unlike traditional therapies that target a single molecular pathway, miR-340 and miR-382 are tumor-suppressive microRNAs capable of regulating multiple cancer-promoting genes simultaneously. Laboratory testing showed that increasing these specific microRNAs impairs tumor cell proliferation, invasion, and self-renewal.
Is this treatment currently available for patients in clinical trials?
Not yet. While the preclinical results in animal and cell models are promising, additional research is required to evaluate safety, optimal dosing, and repeated treatment schedules before the approach can advance into human clinical trials.